Research analysts at Leerink Partners started coverage on shares of Shattuck Labs (NASDAQ:STTK - Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set an "outperform" rating and a $4.00 price target on the stock. Leerink Partners' price target suggests a potential upside of 233.33% from the company's current price.
Shattuck Labs Stock Performance
Shares of Shattuck Labs stock traded up $0.04 during trading on Monday, hitting $1.20. 186,977 shares of the stock were exchanged, compared to its average volume of 379,508. The stock has a market cap of $57.29 million, a PE ratio of -0.78 and a beta of 1.66. The stock's fifty day moving average is $1.24 and its 200 day moving average is $1.59. Shattuck Labs has a 12 month low of $0.94 and a 12 month high of $11.76.
Hedge Funds Weigh In On Shattuck Labs
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Prosight Management LP raised its stake in Shattuck Labs by 15.1% during the 4th quarter. Prosight Management LP now owns 6,638,935 shares of the company's stock valued at $8,033,000 after acquiring an additional 873,409 shares in the last quarter. Millennium Management LLC raised its stake in shares of Shattuck Labs by 37.0% during the fourth quarter. Millennium Management LLC now owns 201,214 shares of the company's stock valued at $243,000 after purchasing an additional 54,322 shares in the last quarter. Deutsche Bank AG lifted its holdings in Shattuck Labs by 476.4% in the fourth quarter. Deutsche Bank AG now owns 116,868 shares of the company's stock worth $141,000 after purchasing an additional 96,594 shares during the period. Bank of America Corp DE grew its position in Shattuck Labs by 135.0% in the 4th quarter. Bank of America Corp DE now owns 187,089 shares of the company's stock valued at $226,000 after buying an additional 107,491 shares in the last quarter. Finally, 683 Capital Management LLC acquired a new position in Shattuck Labs during the 4th quarter valued at about $1,270,000. 58.74% of the stock is owned by institutional investors.
About Shattuck Labs
(
Get Free Report)
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Read More
Before you consider Shattuck Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shattuck Labs wasn't on the list.
While Shattuck Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
